PTT: Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial

Sponsor
University of North Carolina, Chapel Hill (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03886519
Collaborator
Orbis (Other), National Eye Institute (NEI) (NIH), University of Maryland, Baltimore (Other)
900
1
2
48.6
18.5

Study Details

Study Description

Brief Summary

The objective of this study is to determine if there is a significant difference in post-operative trichiasis at 12 months comparing a new procedure, the Bevel/rotate/advance procedure (BRAP), to the Trabut procedure among repeat surgery patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: BRAP (Bevel/rotate/advance procedure)
  • Procedure: Trabut
N/A

Detailed Description

The investigators will randomize participants with previously operated trichiasis on a 1:1 basis to receive either the Bevel/rotate/advance procedure (BRAP) or the Trabut procedure. The participants will be followed at 1 day, 2 weeks, 3-6 months, and then 12 months following the surgery. The primary study endpoint is recurrence of post-operative trichiasis within 12 months of surgery. The investigators will conduct logistic regression analysis comparing post-operative trichiasis recurrent rates in participants receiving BRAP versus participants receiving Trabut. Adjusted analyses will account for demographic characteristics as well as trichiasis severity prior to surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
900 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial
Actual Study Start Date :
Apr 13, 2019
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: BRAP (Bevel/rotate/advance procedure)

The BRAP procedure is a full-thickness beveled full-thickness incision

Procedure: BRAP (Bevel/rotate/advance procedure)
Trichiasis surgery using the BRAP procedure
Other Names:
  • BRAP procedure
  • Active Comparator: Trabut 3 mm

    The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.

    Procedure: Trabut
    Trichiasis surgery using the Trabut procedure
    Other Names:
  • Trabut procedure
  • Outcome Measures

    Primary Outcome Measures

    1. Number of eyelids with post-operative trichiasis within 12 months [10-20 months]

      Presence of post-operative trichiasis defined as at least one trichiatic eyelashes or evidence of recent epilation. Trichiatic eyelashes are eyelashes touching the globe with the eye in the primary gaze. The outcome will be assessed at 3-6 months and at 12 months. If the eyelid has trichiasis at 2 weeks, but not at 3-6 months or 12 months, the eyelid will not be considered to have post-operative trichiasis.

    Secondary Outcome Measures

    1. Number of eyelids with presence of post-operative trichiasis within 3-6 months [3-6 months]

      Presence of post-operative trichiasis defined as at least one trichiatic eyelash or evidence of recent epilation. Trichiatic eyelashes are eyelashes touching the globe with the eye in primary gaze.

    2. Number of eyelids with each of the trichiasis severity levels at 3-6 months [3-6 months]

      Severity will be graded as mild, moderate, or severe based on the number of eyelashes touching the globe and the amount of eyelashes epilated. Trichiasis severity will be defined using the following categories: i. Mild: 1-4 eyelashes touching globe and no epilation OR <1/3 eyelashes epilated and no eyelashes touching the globe ii. Moderate: 5-9 eyelashes touching globe and no epilation OR 1-4 eyelashes touching globe and <1/3 eyelashes epilated iii. Severe: 5-9 eyelashes touching globe and <1/3 eyelashes epilated OR 10+ eyelashes touching globe (regardless of epilation status) OR ≥1/3 eyelashes epilated (regardless of eyelashes touching globe) OR entire eyelid epilated

    3. Number of eyelids with each of the trichiasis severity levels at 12 months [10-20 months]

      Severity will be graded as mild, moderate, or severe based on the number of eyelashes touching the globe and the amount of eyelashes epilated. Trichiasis severity will be defined using the following categories: i. Mild: 1-4 eyelashes touching globe and no epilation OR <1/3 eyelashes epilated and no eyelashes touching the globe ii. Moderate: 5-9 eyelashes touching globe and no epilation OR 1-4 eyelashes touching globe and <1/3 eyelashes epilated iii. Severe: 5-9 eyelashes touching globe and <1/3 eyelashes epilated OR 10+ eyelashes touching globe (regardless of epilation status) OR ≥1/3 eyelashes epilated (regardless of eyelashes touching globe) OR entire eyelid epilated

    4. Change in severity of post-operative trichiasis between 3-6 months and 1 year using grading system [10-20 months]

      The investigators will examine progression of severity between 3-6 months and a year and assess predictors of change in severity. Change will be measured in terms of number of categories between 3-6 month and 1 year outcome. E.g. Mild to Severe would be a 2 category change. Severity will be graded as mild, moderate, or severe based on the number of eyelashes touching the globe and the amount of eyelashes epilated. Trichiasis severity will be defined using the following categories: i. Mild: 1-4 eyelashes touching globe and no epilation OR <1/3 eyelashes epilated and no eyelashes touching the globe ii. Moderate: 5-9 eyelashes touching globe and no epilation OR 1-4 eyelashes touching globe and <1/3 eyelashes epilated iii. Severe: 5-9 eyelashes touching globe and <1/3 eyelashes epilated OR 10+ eyelashes touching globe (regardless of epilation status) OR ≥1/3 eyelashes epilated (regardless of eyelashes touching globe) OR entire eyelid epilated

    5. Number of eyelids with moderate/severe eyelid contour abnormalities at 3-6 months [3-6 months]

      The eye examiner in the field will assess for eyelid contour abnormalities and grade the abnormalities as mild, moderate, or severe. For the analysis, no abnormality and mild eyelid contour abnormality will be combined, and moderate and severe eyelid contour abnormality will be combined. For secondary analyses, the investigators will classify eyelid contour abnormalities using the photographs to capture the full range of ECA categories: none, mild, moderate, and severe. The definitions for the categories are: 1) Mild: Vertical deviation from the natural contour, 1 mm in height (less than half the pupil height in daylight) and affecting 1/3 of horizontal eyelid length. 2) Moderate: Vertical deviation from the natural contour 1-2 mm in height (about the pupil height in daylight) or affecting 1/3-2/3 of horizontal eyelid length 3) Severe: Vertical deviation from the natural contour 2 mm in height (more than the pupil height in daylight) or a defect >2/3 of the horizontal eyelid length

    6. Number of eyelids with moderate/severe eyelid contour abnormalities at 12 months [10-20 months]

      The examiner in the field will assess for eyelid contour abnormalities and grade the abnormalities as mild, moderate, or severe. For the analysis, no abnormality and mild eyelid contour abnormality will be combined, and moderate and severe eyelid contour abnormality will be combined. For secondary analyses, the investigators will classify eyelid contour abnormalities using the photographs to capture the full range of ECA categories: none, mild, moderate, and severe. The definitions for the categories are: 1) Mild: Vertical deviation from the natural contour, 1 mm in height (less than half the pupil height in daylight) and affecting 1/3 of horizontal eyelid length. 2) Moderate: Vertical deviation from the natural contour 1-2 mm in height (about the pupil height in daylight) or affecting 1/3-2/3 of horizontal eyelid length 3) Severe: Vertical deviation from the natural contour 2 mm in height (more than the pupil height in daylight) or a defect >2/3 of the horizontal eyelid length

    7. Cumulative number of eyelids with presence of pyogenic granulomas within 12 months [10-20 months]

      Pyogenic granulomas occasionally develop after trichiasis surgery. It is thought that this is a response to a foreign material, such as a sutures or an incision edge. All granulomas will be noted regardless of size. The investigators will count granulomas observed at the 3-6 month visit (including participants where the granuloma was removed) and granulomas observed at 12 months.

    8. Number of eyelids with other abnormalities at 12 months [10-20 months]

      The eye examiner will examine the eyes for other abnormalities at 12 months: gaps between eyelid and the eye, abnormally thick eyelid, overcorrected eyelids, and infections

    9. Number of eyes with punctate epithelial erosion at 12 months [10-20 months]

      The eye examiner will assess the cornea for signs of corneal damage such as punctate epithelial erosions, using fluorescein staining and a blue light.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Aged 18 or older

    • At least one eyelid with post-operative upper eyelid trichiasis

    • Willing to comply with all study procedures and be available for the duration of the study

    Exclusion Criteria:
    • Inability to provide independent, informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Orbis Ethiopia Hosa'ina Southerns Nations, Nationalities, And Peoples' Region Ethiopia

    Sponsors and Collaborators

    • University of North Carolina, Chapel Hill
    • Orbis
    • National Eye Institute (NEI)
    • University of Maryland, Baltimore

    Investigators

    • Principal Investigator: Emily Gower, PhD, University of North Carolina, Chapel Hill

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of North Carolina, Chapel Hill
    ClinicalTrials.gov Identifier:
    NCT03886519
    Other Study ID Numbers:
    • 17-2766
    • UG1EY025992-04S1
    First Posted:
    Mar 22, 2019
    Last Update Posted:
    Aug 24, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 24, 2022